Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin versus epirubicin TACE combined with HAIC for unresectable hepatocellular carcinoma
ChiCTR2600133818Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idarubicin and epirubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
idarubicinepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600133818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133818.